Valion Bio, Inc. (VBIO) earnings
Quarterly and annual VBIO reports and results, each read against the price at its own news timestamp. Back to the VBIO overview →
4 measured VBIO earnings events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Valion Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.90% | +5.31% | |
| Form 10-Q Valion Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | -3.09% | -9.28% | |
| VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS | Press release | -3.09% | -9.28% | |
| Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026 | Press release | -1.32% | +16.84% |
Keep exploring
More VBIO: analyst actions → · SEC filings → · VBIO overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| VITROLIFE AB UNSP/ADR (VTRLY) | 50 | 0.00% | 0% |
| Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) | 49 | -0.01% | 17% |
| Advaxis, Inc. (ADXS) | 48 | 0.00% | 21% |
| Arch Biopartners Inc (ARCH_CDNX) | 48 | -0.59% | 19% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.